<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04887896</url>
  </required_header>
  <id_info>
    <org_study_id>GS-500-001</org_study_id>
    <nct_id>NCT04887896</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of GS500 in Subjects With Functional Constipation</brief_title>
  <acronym>TRANSIT</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of GS500 in Subjects With Functional Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gelesis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gelesis, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability and efficacy of GS500 as a&#xD;
      superabsorbent hydrogel for relief of constipation in subjects with functional constipation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety, tolerabilityand efficacy of GS500 as a superabsorbent hydrogel for&#xD;
      relief of constipation in subjects with functional constipation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-dose.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoint</measure>
    <time_frame>8 weeks</time_frame>
    <description>Proportion of CSBM Responders defined as subjects with increase of ≥ 1 CSBM from Baseline Run-In during at least 6 of the 8 weeks of the Effectiveness period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Straining score (EoPS)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Constipation severity (self-assessment on 0 to 10 numerical rating scale)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBM stool consistency (BSFS)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBM frequency rate (SBMs/week)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSBM frequency rate (CSBMs/week)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with increase of ≥2 CSBMduringat least6 of the 8 weeks of the Effectiveness period</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Constipation - Functional</condition>
  <arm_group>
    <arm_group_label>GS500 flexible dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3, 2, or 4 GS500 capsules 2 times per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo flexible dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3, 2, or 4 placebo capsules 2 times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GS500</intervention_name>
    <description>Device: GS500</description>
    <arm_group_label>GS500 flexible dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Device: Placebo</description>
    <arm_group_label>Placebo flexible dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 and ≤75 years old&#xD;
&#xD;
          -  BMI ≥18.5 and &lt;35 kg/m2&#xD;
&#xD;
          -  Rome IV criteria for FC&#xD;
&#xD;
          -  Compliant with reporting during Baseline Run-in .&#xD;
&#xD;
          -  Ability to record daily bowel habits, including frequency, stool consistency,&#xD;
             straining, completeness of evacuation, and patient reported outcomes&#xD;
&#xD;
          -  Ability to follow verbal and written instructions&#xD;
&#xD;
          -  Consent obtained via signed ICF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Meeting Rome IV criteria for IBSat screening&#xD;
&#xD;
          -  Missing &gt; 2 days of daily bowel habits reporting during either week of the Baseline&#xD;
             Run-in period&#xD;
&#xD;
          -  Patients reporting laxative, enema, and/or suppository usage for &gt;2 days or any usage&#xD;
             of a prohibited medication during the Baseline Run-in&#xD;
&#xD;
          -  Patients reporting watery stools for any SBM or loose stools for &gt;1 SBM in the absence&#xD;
             of laxatives during Baseline Run-in&#xD;
&#xD;
          -  Need for routine manual maneuvers in the last 6 months in order to achieve a BM&#xD;
&#xD;
          -  History of significant GI lumen surgery at any time or other GI or abdominal surgery&#xD;
             except cholecystectomy or appendectomy within 2 months prior to screening&#xD;
&#xD;
          -  Documented GI obstruction&#xD;
&#xD;
          -  History of laxative abuseas judged by investigator team&#xD;
&#xD;
          -  Glycosylated hemoglobin (HbA1c) ≥8.5%&#xD;
&#xD;
          -  Known history of Crohn's disease or ulcerative colitis&#xD;
&#xD;
          -  Pregnancy in females of childbearing potential or lactation&#xD;
&#xD;
          -  Absence of medically approved contraception in females of childbearing potential&#xD;
&#xD;
          -  History of allergic reaction to carboxymethylcellulose, citric acid, sodium stearyl&#xD;
             fumarate, HPMC, pectin, gelatin, maltotextrin or titanium dioxide&#xD;
&#xD;
          -  Currently enrolled in another investigational device or drug study, or less than 3&#xD;
             months since ending another investigational device or drug study(s), or receiving&#xD;
             other investigational treatment(s).&#xD;
&#xD;
          -  Subjects anticipating surgical intervention during the study&#xD;
&#xD;
          -  Angina, coronary bypass, or myocardial infarction within 6 months prior to Screening&#xD;
             Visit&#xD;
&#xD;
          -  History of swallowing disorders&#xD;
&#xD;
          -  History of gastroparesis&#xD;
&#xD;
          -  History of intestinal stricture (e.g., Crohn's disease)&#xD;
&#xD;
          -  History of intestinal obstruction or subjects at high risk of intestinal obstruction&#xD;
             including suspected small bowel adhesions&#xD;
&#xD;
          -  History of maltodextrin intolerance&#xD;
&#xD;
          -  Presence of metastatic cancer or current use of systemic anti-cancer treatments&#xD;
&#xD;
          -  Anticipated requirement for use of prohibited concomitant medications&#xD;
&#xD;
          -  Current use of prescribed or illicit opioids&#xD;
&#xD;
          -  Use of intestinal secretagogues to treat constipation/IBS within 12 months of the&#xD;
             screening visit&#xD;
&#xD;
          -  Any other clinically significant disease or biochemical abnormality interfering with&#xD;
             the assessments of GS500, according to the Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hassan M Heshmati, MD</last_name>
    <phone>(215) 275 - 1275</phone>
    <email>hheshmati@gelesis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Henry W Calderon, BS</last_name>
    <phone>(857) 201- 5330</phone>
    <email>hcalderon@gelesis.com</email>
  </overall_contact_backup>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

